Astellas receives approval of Evrenzo (roxadustat) in Japan for the treatment of anaemia of chronic kidney disease in adult patients not on dialysis

Astellas

27 November 2020 - Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anaemia of CKD not on dialysis.

Astellas Pharma and FibroGen today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo (roxadustat) for the treatment of anaemia of chronic kidney disease in adult patients not on dialysis.

Read Astellas press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Japan